Originally published as JCO Early Release 10.1200/JCO.2006.10.4323 on September 17 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sargent, D. J. Articles by de Gramont, A. Search for Related Content PubMed PubMed Citation Articles by Sargent, D. J. Articles by de Gramont, A. Social Bookmarking                            What's this?

End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group

Daniel J. Sargent, Smitha Patiyil, Greg Yothers, Daniel G. Haller, Richard Gray, Jacqueline Benedetti, Marc Buyse, Roberto Labianca, Jean Francois Seitz, Christopher J. O'Callaghan, Guido Francini, Axel Grothey, Michael O'Connell, Paul J. Catalano, David Kerr, Erin Green, Harry S. Wieand, Richard M. Goldberg, Aimery de Gramont

From the Departments of Health Sciences Research and Medical Oncology, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN; Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project Statistical Center and Operations Office, Pittsburgh; Abramson Cancer Center, University of Pennsylvania; the Department of Human Oncology, Allegheny General Hospital Philadelphia, PA; Southwest Oncology Group Statistical Center; Fred Hutchinson Cancer Research Center, Seattle, WA; Eastern Cooperative Oncology Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard University, Boston, MA; Department of Hematology/Oncology, University of North Carolina, Chapel Hill, NC; Quick and Simple and Reliable Collaborative Group, Clinical Trials Unit, University of Birmingham, Birmingham and the Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom; International Drug Development Institute, Brussels Belgium; Unit Medical Oncology, Ospedali Riuniti, Bergamo; Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy; Gastroenterology Unit, C.H.U. la Timone; University of the Mediterranean, Marseilles; Hospital Saint Antoine, Paris, France; and the National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, Canada

Address reprint requests to Daniel J. Sargent, PhD, Mayo Clinic, 200 First St SW, Harwick 8-27, Rochester, MN 55905; e-mail: sargent.daniel{at}mayo.edu

Purpose The traditional end point for colon adjuvant clinical trials is overall survival (OS). We previously validated disease-free survival (DFS) after 3-year follow-up as an excellent predictor of 5-year OS results. Here we explore shorter term DFS and OS end points, as well as stage dependency.

Methods Individual patient data from 18 phase III trials including 43 arms and 20,898 patients were pooled. Association measures included correlation of event rates within arms, correlation of hazard ratios (HRs) between arms, trial level significance comparisons (via log-rank testing), and a formal surrogacy model.

Results DFS at earlier times was less accurate in predicting OS than 3-year DFS, but 2-year DFS remained a strong predictor. DFS with 1-year minimum follow-up demonstrated perfect negative predicted value; all trials negative at 1 year for DFS were negative for 5-year OS. OS with 3-year minimum follow-up was also an excellent predictor for 5-year OS; OS at earlier time points provided inaccurate prediction. The association between 3-year DFS and 5-year OS was greater for stage III patients; correlation of HR within trials was 0.92 (95% CI, 0.85 to 0.95) for stage III patients and 0.70 (95% CI, 0.44 to 0.80) for stage II patients.

Conclusion DFS outcomes after 2- or 3-year median follow-up are excellent predictors of 5-year OS. DFS outcomes are appropriate for trials in which the majority of patients are stage III. DFS after 2- or 3-year median follow-up should be considered as the primary end point in future colon adjuvant trials.

published online ahead of print at www.jco.org on September 17, 2007.

Supported by National Cancer Institute Grant No. CA25224.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. de Gramont, D. G. Haller, D. J. Sargent, J. Tabernero, A. Matheson, and R. L. Schilsky Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program J. Clin. Oncol., February 1, 2010; 28(4): 527 - 530. [Full Text] [PDF]

				A. de Gramont, J. Hubbard, Q. Shi, M. J. O'Connell, M. Buyse, J. Benedetti, B. Bot, C. O'Callaghan, G. Yothers, R. M. Goldberg, et al. Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set J. Clin. Oncol., January 20, 2010; 28(3): 460 - 465. [Abstract] [Full Text] [PDF]

				A. Sanchez-Munoz, N. Ribelles, A. Marquez, E. Perez-Ruiz, and E. Alba Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: Overall Survival Versus Disease-Free Survival As a Primary End Point in Clinical Practice J. Clin. Oncol., December 10, 2009; 27(35): e255 - e256. [Full Text] [PDF]

				N. Methy, L. Bedenne, T. Conroy, O. Bouche, O. Chapet, M. Ducreux, J.-P. Gerard, and F. Bonnetain Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial Ann. Onc., September 16, 2009; (2009) mdp340v1. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 J. Clin. Oncol., July 1, 2009; 27(19): 3117 - 3125. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, J. Oliveira, and On behalf of the ESMO Guidelines Working Group Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv49 - iv50. [Full Text] [PDF]

				D. Sargent, A. Sobrero, A. Grothey, M. J. O'Connell, M. Buyse, T. Andre, Y. Zheng, E. Green, R. Labianca, C. O'Callaghan, et al. Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials J. Clin. Oncol., February 20, 2009; 27(6): 872 - 877. [Abstract] [Full Text] [PDF]

				B. Seruga and I. F. Tannock Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes J. Clin. Oncol., February 20, 2009; 27(6): 840 - 842. [Full Text] [PDF]

				B. Besse and T. Le Chevalier Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect? J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017. [Full Text] [PDF]